Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Aamir SaifuddinAlexandra J KentShameer J MehtaLucy C HicksHaidee Aleman GonzalezJonathan P SegalMatthew James BrookesSreedhar SubramanianNeeraj BhalaThomas Edward ConleyKamal V Patelnull nullChristopher Andrew LambGareth J WalkerNicholas Alexander KennedyShaji SebastianPublished in: Alimentary pharmacology & therapeutics (2022)
Despite treatment adaptations during the pandemic, steroid-free outcomes were comparable with pre-pandemic levels, although concurrent flare and suspected COVID-19 caused worse outcomes. These findings have implications for IBD management during future pandemics and for standard practice.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- newly diagnosed
- clinical trial
- ejection fraction
- healthcare
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- pulmonary embolism
- squamous cell carcinoma
- metabolic syndrome
- skeletal muscle
- radiation therapy
- combination therapy
- locally advanced
- rectal cancer
- double blind
- patient reported